JPRN-jRCT2080221773未知3 期
Phase 3 clinical study of RM-003 in patients with homocystinuria
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Homocystinuria, described as the following cases
- •- cystathionine beta-synthase deficiency(CBS)
- •- 5,10-methylenetetrahydrofolate reductase deficiency
- •- defects in cobalamin metabolism
排除标准
- 未提供
研究者
相似试验
未知
3 期
Phase 3 clinical study of MRA in patients with systemic juvenile idiopathic arthritis (sJIA)sJIAJPRN-jRCT2080220017Chugai Pharmaceutical Co., Ltd.
进行中（未招募）
1 期
Reversal of dabigatran anticoagulant effect with idarucizumabHemorrhageMedDRA version: 19.0Level: LLTClassification code 10019524Term: HemorrhageSystem Organ Class: 100000004866EUCTR2013-004813-41-DKBoehringer Ingelheim Danmark A/S500
已完成
3 期
A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.hemorragisce strokeemergency surgery/procedure + uncontrolled bleeding1000318410047079NL-OMON42113Boehringer Ingelheim6
进行中（未招募）
1 期
Reversal of dabigatran anticoagulant effect with idarucizumabHemorrhageMedDRA version: 18.1Level: LLTClassification code 10019524Term: HemorrhageSystem Organ Class: 100000004866EUCTR2013-004813-41-NLBoehringer Ingelheim bv500
进行中（未招募）
1 期
Reversal of dabigatran anticoagulant effect with idarucizumabEUCTR2013-004813-41-ITBoehringer Ingelheim Italia S.p.A.250